All In Biotech

NDA 017442 · Pfizer

Minipress

Prazosin Hydrochloride · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jan 8, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1976

Jun 23, 1976

Approved uses

1

Original approval plus efficacy supplements

Registered trials

114

9 Phase 3, 2 recruiting

FAERS reports

1,387

873 serious, 91 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 5, 2026.

INDICATIONS AND USAGE Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 23, 1976 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
  • MINIPRESS · PRAZOSIN HYDROCHLORIDE EQ 2MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • MINIPRESS · PRAZOSIN HYDROCHLORIDE EQ 5MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • MINIPRESS · PRAZOSIN HYDROCHLORIDE EQ 1MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Prazosin" as an intervention, any sponsor and status, largest first.

All 114 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue115
  • off label use106
  • abdominal pain105
  • product dose omission issue104
  • drug ineffective91
  • nausea89
  • diarrhoea75
  • pain74
  • renal impairment72
  • heart failure with preserved ejection fraction69
  • headache67
  • dyspnoea63

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
20059
20066
20084
200915
201022
201112
201221
201318
201412
201514
201616
201722
201817
201932
202047
202165
2022177
2023144
2024244
2025298
2026183

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 589 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.